Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/NEUROSENSE-THERAPEUTICS-L-130483704/news/NeuroSense-Therapeutics-Ltd-s-Phase-2b-ALS-Trial-Achieves-Primary-Safety-and-Tolerability-Seconda-45504100/?utm_source=whatsapp&utm_medium=social&utm_campaign=share